Addex Therapeutics

Update in progress

ADXN (NasdaqCM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule medicines for neurological disorders in Switzerland. It targets G‑protein coupled receptors and enzymes. Lead programs include Dipraglurant, in phase 1 for post-stroke/TBI recovery and Parkinson’s disease levodopa‑induced dyskinesia; and ADX71149, a novel orally active mGlu2 positive allosteric modulator. It also develops GABAB PAMs for pain, anxiety, addiction, cough, and overactive bladder. Partners include Janssen and Indivior. Founded 2002; based in Geneva.

Company score

Sentiment: 0.31; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.00; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.00; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.00; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.16; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive